Processa Pharmaceuticals announced key leadership appointments including a new COO and executives for research, development, and business operations to support growth. These moves follow its acquisition of Vidya Therapeutics and a $200 million financing, underpinning its clinical programs for VT-7208, a next-gen oral BTK inhibitor targeting immune diseases like food allergy and multiple sclerosis. The company recently received FDA clearance for a Phase 2 study in chronic spontaneous urticaria and is expanding its pipeline with a neonatal Fc receptor antagonist program. This leadership team aims to accelerate development and capitalize on emerging opportunities.
Processa Pharmaceuticals' leadership changes provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 23 fell. Notable movers include TLRY at USD 2.77 with a 1-day change of +4.53% and a typical hold time of 32 days, VRTX at USD 554.38 with a 1-day change of +4.45% and a typical hold time of 123 days, and SYRE at USD 95.04 with a 1-day change of -4.26% and a typical hold time of 5 days.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
